wla(warner lambert) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Anthony Wong who wrote (617)	3/25/1999 2:13:00 PM
From: Brian Malloy	of 942

Thanks for your post I think the last couple of paragraphs which I paste below are key and pretty much sum up my feelings and why I think WLA will be down next week. Analysts will crunch over the FDA report over the weekend and I believe revisions will be made next week and they are unlikely to be upward revisions. "Regardless of Friday's outcome, the controversy surrounding Rezulin could become moot later this year when two competing drugs are expected to hit U.S. pharmacies, experts and analysts said. Clinical trials on those drugs, SmithKline Beecham's <SB.L> Avandia and Takeda Chemical Industries' <4502.T> Actos, have shown similar effectiveness without any liver damage. "This drug is not going to survive," predicted Dr. Sidney Wolfe, a consumer advocate who will argue for Rezulin's withdrawal at the Friday meeting. "Even if it stays on the market, no one is going to prescribe it if either one of these drugs gets approved." " While you can not count your chickens before they hatch I would say there is a 95%+ chance that both of these drugs will be approved with at least one introduced this summer. Regards,

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next